Released Feb 27, 2023, before the open
10-K filed Feb 27, 2023, 58 days after period end · 0001558370-23-002102
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$8.62M$8.62M derived+0.8% vs Q4 2021−39.2% vs Q3 2022
Net Income-$3.74M-$3.74M derivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$2,495,000N/M
Operating Cash Flowderived-$2,611,000N/M
Free Cash Flowderived-$2,824,000N/M
Margins · derived
Operating margin-29.0%+37.8 pt vs Q4 2021
Net margin-43.4%+34.6 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $8.62M | $8.55M | $19.50M | $17.76M |
| Net Income | -$3.74M | -$6.67M | $397.00K | $291.00K |
| EPS Diluted | — | — | — | $0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR